Skip to Content
Søk Menu

ASCO GU 2024: Updated Results from AVENANCE – Real-World Effectiveness of Avelumab in Patients with Advanced Urothelial Carcinoma

This article presents updated insights from the AVENANCE study about the role of avelumab in advanced urothelial carcinomas.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Mansoor Raza Mirza

ESMO: Update on the ENGOT-EN6 RUBY Trial

/ Mansoor Raza Mirza
ESMO24Gynekologisk kreft Play the Video 02:46
Mansoor Raza Mirza

Mansoor Raza Mirza: ESMO is the Meeting Which Brings New Data for Forever Practice-Changing Trials

/ Mansoor Raza Mirza
ESMO24Gynekologisk kreft Play the Video 04:00
Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatakreft Play the Video 1:31
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrekreft Play the Video 1:47
Eddy Saad

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

/ Eddy Saad
ASCOGU24Nyrekreft Play the Video 2:21
Renee Maria Saliby

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

/ Renee Maria Saliby
ASCOGU24Nyrekreft Play the Video 2:46
Philipp Ivanyi

Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma

/ Philipp Ivanyi
ASCOGU24Nyrekreft Play the Video 3:16
Ahmed Rehan

Real-World Data on Maintenance Avelumab Treatment

/ Ahmed Rehan
ASCOGU24Blærekreft Play the Video 2:14

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

/ Sofie Pohl
ASCOGU24Nyrekreft
Back to top